FDA approves Edwards' porcine replacement heart valve:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Edwards Lifesciences' Carpentier-Edwards SAV porcine replacement heart valve, which the firm says has a 20-year history outside of the US. The bioprosthesis allows for supra-annular implantation - above a patient's native aortic valve, rather than directly into the aortic annulus - and a proprietary scalloped sewing band for optimising anatomic fit. Supra-annular placement allows surgeons to implant a larger-orifice valve, which provides improved haemodynamic performance over intra-annularly placed porcine aortic heart valves, explains the Irvine, California firm. The valve also features Edwards' XenoLogiX tissue treatment.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.